Abbott (NYSE:ABT) and Bigfoot Biomedical said today that the companies inked a deal to develop and commercialize diabetes management systems.
The collaboration will bring together Abbott’s FreeStyle Libre glucose monitoring tech and Bigfoot’s insulin delivery platform, the companies reported.
Get the full story at our sister site, Drug Delivery Business News.
The post Bigfoot Biomedical taps Abbott to collaborate on automated insulin delivery tech appeared first on MassDevice.